



09 JUL 2007

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

FOLEY AND LARDNER LLP
SUITE 500
3000 K STREET NW
WASHINGTON, DC 20007

In re Application of GROUX et al
U.S. Application No.: 10/579,078
PCT Application No.: PCT/IB2004/003882
Int. Filing Date: 05 November 2004
Priority Date Claimed: 12 November 2003
Attorney Docket No.: 065691-0443
For: USE OF LIPOPEPTIDES FOR
ACTIVATING T LYMPHOCYTES
THROUGH THE SKIN

DECISION

This is in response to applicant's "Petition Under 37 C.F.R. § 1.47(a)" filed 15 June 2007.

BACKGROUND

On 05 November 2004, applicant filed international application PCT/IB2004/003882, which claimed priority of an earlier France application filed 12 November 2003. A copy of the international application was communicated to the USPTO from the International Bureau on 26 May 2005. The thirty-month period for paying the basic national fee in the United States expired on 12 May 2006.

On 11 May 2006, applicant filed national stage papers in the United States Designated/Elected Office (DO/EO/US). The submission was accompanied by, *inter alia*, the basic national fee required by 35 U.S.C. 371(c)(1) and an executed declaration.

On 16 November 2006, the DO/EO/US mailed a Notification of Missing Requirements Under 35 U.S.C. 371 (Form PCT/DO/EO/905), which indicated that the declaration filed 11 May 2006 did not identify the application to which it is directed.

On 15 June 2007, applicant filed the present petition under 37 CFR 1.47(a).

On 29 June 2007, this Office mailed a decision dismissing as moot the 15 June 2007 petition.

DISCUSSION

A review of the application file for international application PCT/IB2004/003382 reveals that the declaration under PCT Rule 4.17 was submitted subsequent to the date on which the international application papers were filed. The declaration does not properly identify the application to which it is directed.

A petition under 37 CFR 1.47(a) must be accompanied by: (1) an oath or declaration by each applicant on his or her own behalf and on behalf of the nonsigning joint inventors, (2) factual proof that the missing joint inventors refuse to join in the application or cannot be reached after diligent effort, (3) the fee set forth in §1.17(i), and (4) the last known addresses of the nonsigning joint inventors.

With regard to item (1) above, applicant has submitted a declaration signed by the available inventors each on his/her own behalf and on behalf of the nonsigning inventor.

With regard to item (2) above, MPEP 409.03(d) states in relevant part,

Where a refusal to sign the application papers is alleged, the circumstances of this refusal must be specified in an affidavit or declaration by the person to whom the refusal was made. Statements by a party not present when an oral refusal is made will not be accepted.

Before a refusal can be alleged, it must be demonstrated that a bona fide attempt was made to present a copy of the application papers (specification, including claims, drawings, and oath or declaration) to the nonsigning inventor for signature. A copy of the application papers should be sent to the last known address of the nonsigning inventor, or, if the nonsigning inventor is represented by counsel, to the address of the nonsigning inventor's attorney.

When there is an express oral refusal, that fact along with the time and place of the refusal must be stated in the affidavit or declaration. When there is an express written refusal, a copy of the document evidencing that refusal must be made part of the affidavit or declaration.

When it is concluded by the 37 CFR 1.47 applicant that a nonsigning inventor's conduct constitutes a refusal, all facts upon which that conclusion is based should be stated in the affidavit or declaration. If there is documentary evidence to support facts alleged in the affidavit or declaration, such evidence should be submitted. Whenever a nonsigning inventor gives a reason for refusing to sign the application oath or declaration, that reason should be stated in the affidavit or declaration.

The petition states that joint inventor Herve Groux refuses to sign the application papers. Petitioner has adequately demonstrated that a bona fide attempt was made to present a copy of the application papers to Groux for signature (see affidavit of Jacques Warcoin, ¶5 and Attachment D). Furthermore, the petition sufficiently demonstrates Groux's refusal to sign. Specifically, Groux made an express written refusal on two occasions (see Warcoin's affidavit, ¶¶6,8 and Attachments E,H). Thus, it can be concluded with reasonable certainty that Groux refuses to join in the application.

With regard to item (3) above, applicant is advised that effective 22 November 2004, the fee for a petition under 37 CFR 1.47 increased to \$200.00. Any deficiency in the petition fee will be charged to Deposit Account No. 19-0741 as authorized by applicant.

With regard to item (4) above, the petition states the last known address of the nonsigning inventor.

CONCLUSION

For the reasons above, the decision mailed 29 June 2007 is VACATED.

The petition under 37 CFR 1.47(a) is GRANTED.

The application has an International Filing Date under 35 U.S.C. 363 of 05 November 2004, and a date under 35 U.S.C. 371(c)(1), (c)(2), and (c)(4) of 16 June 2007.

As set forth in 37 CFR 1.47(a), a notice of the filing of this application will be forwarded to the nonsigning inventor at the last known address of record and will be published in the *Official Gazette*.

This application is being forwarded to the United States Designated/Elected Office (DO/EO/US) for further processing in accordance with this decision.

Bryan Lin

Bryan Lin
PCT Legal Examiner
PCT Legal Office

Telephone: 571-272-3303
Facsimile: 571-273-0459

07/09/2007 SBASHEIK 00000004 190741 10579078
Sale Ref: 00000005 DAH: 190741 10579078
01 FC:1463 70.00 DA 130.00 OP



09 JUL 2007

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

Herve Groux
13 chemin des Combes
06560 Le Rouret
FRANCE

In re Application of GROUX et al
U.S. Application No.: 10/579,078
PCT Application No.: PCT/IB2004/003882
Int. Filing Date: 05 November 2004
Priority Date Claimed: 12 November 2003
For: USE OF LIPOPEPTIDES . . .

Dear Herve Groux:

You are named as a joint inventor in the above-captioned United States national stage application, filed under the provisions of 37 CFR 1.47(a) and 35 U.S.C. 116. Should a patent be granted, you will be designated as an inventor.

As a named inventor, you are entitled to inspect any paper in the file wrapper of the application, order copies of all or any part thereof (at a prepaid cost set forth in 37 CFR 1.19) or to make your position of record in the application. Alternatively, you may arrange to do any of the preceding through a registered patent agent or attorney presenting written authorization from you. If you choose to join in the application, counsel of record (see below) would presumably assist you. Joining in the application would entail the filing of an appropriate oath or declaration by you pursuant to 37 CFR 1.63.

Bryan Lin

Bryan Lin
PCT Legal Examiner
PCT Legal Office
Telephone: 571-272-3303
Facsimile: 571-273-0459

FOLEY AND LARDNER LLP
SUITE 500
3000 K STREET NW
WASHINGTON, DC 20007
Attorney Docket No.: 065691-0443